|
⚲
|
| Keyboard |
| Commodore Capital LP
✚
|
|
|---|---|
| CRD # | 304370 |
| SEC # | 801-117168 |
| CIK # | 0001831942 |
| AUM | 2,369.3 M (2026-03-31) |
| Employees | 12 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-256-8600 |
| Address | 444 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION The fees applicable to each of the Funds are set forth in detail in the corresponding Offering Documents. A brief summary of such fees is provided below. Management Fee Commodore charges the Funds a management fee based on the value of the Funds’ assets under management (the “Management Fee”). The Management Fee ranges from 1.5% to 1.75% (per annum) of the net assets of the Funds and is charged monthly in advance on the first business day of each calendar month. The Management Fee is prorated for any period that is less than a full month. Commodore has the authority to waive, reduce or calculate differently the Management Fee with respect to any Investor in its sole discretion, including Investors that are partners, affiliates or employees of Commodore or the General Partner, members of the immediate family of such persons and trusts or other entities established by them or for their benefit and certain other persons in the discretion of Commodore. For Special Investments, the Management Fee is charged on the lower of value or cost of such Special Investment. Incentive Allocation Commodore and/or the General Partner may be paid performance-based compensation, which is compensation that is based on a share of capital gains on or capital appreciation of the assets of the Funds. The General Partner is entitled to a performance allocation from the Funds that ranges from 17.5% to 20% of the net profits (including net unrealized gains) allocated to an Investor over a three- to five-year period (the “Incentive Allocation Period”), subject to a loss carryforward provision. Depending on the circumstances, the performance allocation with respect to Special Investments is calculated either at the time of realization or at the end of the next Incentive Allocation Period. The General Partner has the authority to waive, reduce or calculate differently the amount of performance allocation with respect to any Investor in its sole discretion, including Investors that are partners, affiliates or employees of Commodore or the General Partner, members of the immediate family of such persons and trusts or other entities established by them or for their benefit and certain other persons in the discretion of Commodore. Expenses In addition to paying Management Fees and performance-based compensation (if applicable), the Funds will be subject to other expenses in accordance with their respective governing documents. Such expenses include, without limitation: organizational expenses, including legal expenses and fees of any placement agent or other broker; expenses related to compliance with applicable law or regulation, including expenses related to U.S. and non-U.S. regulatory filings, compliance with the Alternative Investment Fund Managers Directive 2011/61/EU, “blue sky” and “world sky” filings and anti-money laundering laws and regulations; investment-related expenses (whether or not such investments are consummated), including commissions, interest expenses and other indebtedness, investment-related legal costs, custodial fees, brokerage and transaction costs, research and investment-related travel expenses, professional fees for consultants, “expert networks,” “sourcing” consultants and other similar persons, data and research-related expenses (including news and quotation equipment and services), costs of portfolio exposure and performance reporting, risk management and trade order management expenses; ongoing operating expenses, including administrative expenses for regulatory and legal compliance, accounting and tax accounting, communications equipment and services and other back-office and mid-office services (including administrator fees and expenses), litigation, investigation and indemnity expenses, audit, tax preparation and related advisory expenses, insurance costs (including directors’ and officers’ insurance, errors and omissions insurance, cybersecurity insurance and other similar policies), expenses of preparing and distributing reports to Investors (including financial statements, tax returns and other reports), taxes, expenses of communications and meetings with Investors, and extraordinary expenses. Certain expenses may be attributable to more than one Client. Such shared expenses will, to the extent permitted by the Clients’ governing documents, generally be apportioned among all participating Clients pro rata based on, without limitation and depending on the nature of the expense, position size, fund size (i.e., capital commitments or net asset value, as applicable), available cash, or in any other manner deemed equitable by Commodore. The Firm seeks to allocate shared expenses for products and services benefitting Commodore and the Client and not explicitly covered in the Client’s arrangements in a fair and reasonable manner. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS Our current Clients are the Funds, as described in Item 4 above. The Funds are generally open to, among others, institutions, pension plans, endowments, high net-worth individuals, financially sophisticated individuals, and other sophisticated investors. There are minimum investment requirements for investors in the Funds. In all cases, the minimum investment required for a Fund is subject to waiver by Commodore to the extent permitted by applicable law. Details can be found in the respective Offering Documents of the Funds. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Relay Therapeutics Inc | 0.2 | ||
| Alkermes PLC | 0.1 | ||
| Imara Inc | 0.1 | ||
| UNUM Therapeutics Inc | 0.1 | ||
| Aeglea Biotherapeutics Inc | 0.1 | ||
| TYRA Biosciences Inc | 0.1 | ||
| Celldex Therapeutics Inc | 0.1 | ||
| Nuvalent Inc | 0.1 | ||
| Amylyx Pharmaceuticals Inc | 0.1 | ||
| Kymera Therapeutics Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Commodore Capital Master LP | [2019-07-15] | 891.5 M | 2,369.3 M |
| Filed 2026-02-25 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 2.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 2.4 |
| By Discretionary | ||
| Discretionary | 3 | 2.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 2.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.7 | |
| United States Persons | 1.6 | |
| Total | 3 | 2.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Commodore Capital LP | Executive Officer | 2 | 2 | |
| Michael Kramarz | Executive Officer | 2 | 2 | |
| Egen Atkinson | Executive Officer | 2 | 2 | |
| Commodore Capital Domestic GP LP | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001831942] | |
| 3 | [0001831942] | |
| 4 | [0001831942] | |
| SC 13G | [0001831942] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300729275T4UVFT94 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Vera Therapeutics Inc | |
| Commodore Capital LP | |
| Vistagen Therapeutics Inc | |
| Ambrx Biopharma Cayman Inc | |
| Enliven Therapeutics Inc | |
| Satsuma Pharmaceuticals Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Vera Therapeutics Inc VERA
Class A Common Stock
|
2024-01-10 | Sell | 1,050,000 | $18.00 | 18,900,000 |
|
Vistagen Therapeutics Inc VTGN
Pre-Funded Warrants (Right to Buy) · derivative
|
2023-10-04 | Grant | 2,788,620 | ||
|
Vistagen Therapeutics Inc VTGN
Tranche 1 Warrants (Right to Buy) · derivative
|
2023-10-04 | Grant | 1,394,310 | ||
|
Vistagen Therapeutics Inc VTGN
Tranche 2 Warrants (Right to Buy) · derivative
|
2023-10-04 | Grant | 1,690,014 | ||
|
Vistagen Therapeutics Inc VTGN
Common Stock
|
2023-08-07 | Buy | 775,756 | $23.15 | 17,958,751 |
|
Vera Therapeutics Inc VERA
Class A Common Stock
|
2023-06-20 | Buy | 448,217 | $15.17 | 6,799,452 |
|
Enliven Therapeutics Inc ELVN
Common stock, par value $0.001 per share
|
2023-02-23 | Other | 729,891 | ||
|
Enliven Therapeutics Inc ELVN
Common stock, par value $0.001 per share
|
2023-02-23 | Buy | 621.75 | $22.07 | 13,722 |
|
Enliven Therapeutics Inc IMRA
Common stock, par value $0.001 per share
|
2023-02-22 | Buy | 23,565 | $5.11 | 120,417 |
|
Enliven Therapeutics Inc IMRA
Common stock, par value $0.001 per share
|
2023-02-21 | Buy | 8,194 | $5.25 | 43,018 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2022-11-14 | Sell | 3,250,000 | $0.71 | 2,307,500 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-24 | Buy | 2,922 | $5.42 | 15,837 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-22 | Buy | 9,979 | $5.49 | 54,785 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-19 | Buy | 3,225 | $5.44 | 17,544 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-11 | Buy | 7,941 | $6.05 | 48,043 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-10 | Buy | 9,622 | $5.85 | 56,289 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-08 | Buy | 560 | $5.99 | 3,354 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-05 | Buy | 7,800 | $5.95 | 46,410 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-04 | Buy | 1,400 | $5.88 | 8,232 |
|
Satsuma Pharmaceuticals Inc STSA
Common Stock, par value $0.0001 per share
|
2021-11-02 | Buy | 8,880 | $5.64 | 50,083 |
| showing 20 of 29 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Alatus Capital LLC
✚
|
2,398.4 M | |
|
Heard Capital LLC
✚
|
IL | 2,395.9 M |
|
Ram Active Investments Sa
✚
|
2,393.2 M | |
|
Nordflint Capital Partners Fondsmaeglerselskab A/S
✚
|
2,392.2 M | |
|
Mudita Advisors LLP
✚
|
2,383.3 M | |
|
Cartenna Capital LP
✚
|
CT | 2,359.2 M |
|
AFBI LP
✚
|
FL | 2,342.4 M |
|
Actusraypartners Limited
✚
|
2,339.2 M | |
|
ISAM Funds UK Limited
✚
|
2,333.7 M | |
|
ISAM Funds USA LLC
✚
|
FL | 2,333.7 M |